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Abstract Respiratory syncytial virus (RSV) is the lead-
ing viral pathogen responsible for bronchiolitis and pneu-
monia in infants. We assessed palivizumab prophylaxis
compliance for infants in Puerto Rico. We retrospectively
studied data from 868 infants (409 females, 459 males)
during the 2009–2010 RSV season. The infants had a mean
gestational age of 33 weeks (range 23–41) and a mean
birth weight of 1,767 g (range 509–4,120). Only 74 % of
the infants with indications received prophylaxis. The main
reasons for noncompliance were non-approval by the
medical insurance (53 %), parents’ unavailability (31 %),
and infant sickness (11 %). Infants with the government
medical insurance were more likely to be denied prophy-
laxis and to receive fewer doses. Parents need to be edu-
cated on the importance of RSV prophylaxis. Physicians
should be aware that many infants are not being dosed
appropriately and that strategies need to be established to
improve compliance.
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Introduction
Respiratory syncytial virus (RSV) is the leading viral
pathogen responsible for bronchiolitis and pneumonia in
infants during the first year of life in the United States. The
risk of serious RSV illness is highest among those with
prematurity, bronchopulmonary dysplasia (BPD), chronic
lung disease (CLD), congenital heart disease (CHD), con-
genital abnormalities of the airway or neuromuscular dis-
ease, and certain immunodeficiencies. Eighty to ninety
percent of infant hospitalizations are RSV-related and the
majority of these occur in children younger than 6 months
of age [1].
The prevention of this infection is available with intra-
muscular humanized monoclonal antibody (palivizumab).
Palivizumab has been found to be safe in doses of 15 mg/kg
administered by intramuscular injection every 28–30 days
during the RSV season. In 1998, the results of a multicenter,
multinational, phase III trial (IMpact-RSV) to evaluate the
safety and effectiveness of monthly administration of pali-
vizumab as prophylaxis for serious RSV illness in high-risk
infants was published. Palivizumab reduced the incidence
of hospitalization due to RSV compared to placebo by 55 %
[2, 3]. Children randomized to palivizumab had fewer days
of RSV hospitalization and fewer days of supplemental
oxygen therapy. The authors reported that intramuscular
injections were well tolerated and there were no toxicities
associated [3].
In Puerto Rico, RSV infections are seen throughout the
year with a peak season starting in July and ending in March.
In 2009, the American Academy of Pediatrics (AAP) pub-
lished new guidelines for RSV prophylaxis recommending
fewer doses for premature infants born at 32–35 weeks of
gestation in all geographical areas. Recommendations for
initiation and termination of prophylaxis were modified to
reflect current descriptions from the Centers for Disease
Control and Prevention (CDC) of RSV seasonality in dif-
ferent geographic locations within the United States.
Regardless of the month in which the first dose is adminis-
tered, the recommendation for a maximum number of 5
doses for all geographic locations is emphasized for infants
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with hemodynamically significant CHD, CLD, or birth
before 32 weeks’ 0 days’ gestation. A maximum number of
three doses were recommended for infants with a gestational
age of 32 weeks 0 days to 34 weeks 6 days without hemo-
dynamically significant CHD or CLD who qualify for pro-
phylaxis [4]. Due to the year round prevalence of RSV in
Puerto Rico infants in the island were eligible to receive up to
nine doses of palivizumab during the RSV season. After the
new AAP statement was released, the Puerto Rico Health
Department made the resolution to follow their recommen-
dations, and decreased the number of doses given.
We studied the data of all the infants who received RSV
prophylaxis during the 2009–2010 RSV season in Puerto
Rico, distributed by one specific specialty pharmacy with
the objectives of assessing if infants at risk of RSV
infection were receiving palivizumab as recommended by
the 2009 AAP guidelines and evaluating the reasons for
noncompliance.
Materials and Methods
We retrospectively analyzed deidentified data from a
cohort of patients receiving palivizumab. The data was
collected from the Special Care Pharmacy and Com-
pounding Services database for patients who were eligible
to receive RSV prophylaxis during the 2009–2010 RSV
season in Puerto Rico (from July 2009 to March 2010).
Special Care Pharmacy was the main distributor of pali-
vizumab in Puerto Rico providing services to approxi-
mately 90 % of the infants referred for RSV prophylaxis.
They collected data prospectively during the season which
was made available to us without identifiers. Data included
demographics, eligibility for palivizumab, medical insur-
ance approval, number of doses received and interval
between doses. Subjects from all over the island and from
every medical insurance, private and government were
included.
The statistical analysis of collected data was performed
by using frequency, means, median, and ranges. Differ-
ences among groups were evaluated using Chi square and
t test. A p value \0.05 were considered statistically sig-
nificant. The study was approved by the University of
Puerto Rico Medical Sciences Campus Institutional
Review Board.
Results
The data of 868 infants (47 % females, 53 % males) who
qualified to receive RSV prophylaxis during the 2009–2010
RSV season were evaluated. The mean gestational age of
the infants was 33 weeks (range 23–41), and the mean birth
weight was 1,767 g (range 509–4,120). Figure 1 shows the
distribution of subjects by risk group who were eligible to
receive palivizumab prophylaxis. Most of them (55 %)
were premature infants born at 32 1/7–35 weeks of gesta-
tion followed by those born at 29–32 weeks of gestation.
Infants were equally distributed with regard to government
(public) medical insurance (50 %) and private insurances
(50 %).
Seventy-four percent of the infants (n = 640) referred to
the specialty pharmacy received at least one dose of pali-
vizumab prophylaxis in the studied season. The median
number of doses administered was 2 (range 1–9), and the
median interval between the doses was 32 days (range
23–123). The total number of palivizumab doses received
by all infants was 1,163 and 69 % of the doses (n = 806)
were administered in intervals not [35 days. Six percent
of the doses (n = 68) were administered in intervals of
\28 days.
Of those patients that qualified to receive a maximum of
five doses, infants born at \32 weeks of gestation and
those with CHD received a median of three doses. Infants
with CLD received a median of 4 doses. Of those patients
that qualified to receive a maximum of three doses, infants
born at 32 1/7–35 weeks of gestation received a median of
two doses. The difference in maximum doses between
these groups was significant (p \ 0.01). The maximum
number of five doses was received by 27 % of infants born
at\32 weeks of gestation, 31 % of infants with CHD, and
47 % of those with CLD. The maximum number of three
doses was received by 36 % of infants born at 32
1/7–35 weeks of gestation. Only 16 % of the patients
received their first dose before discharge from the hospital.
The reasons for noncompliance with the recommended
regimen of RSV prophylaxis were non-approval by the
medical insurance (53 %) followed by unavailability of the
parents (31 %), sick infant (11 %), not being able to afford
co-pay (3 %), lack of transportation (1 %), and no interest
in the prophylaxis (1 %).
After the implementation of the 2009 AAP guidelines,
infants born at 32 1/7–35 weeks of gestation were more
likely to be denied prophylaxis (p \ 0.01). RSV
Fig. 1 Distribution of risk groups eligible to receive palivizumab in
the studied population (N = 868)
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prophylaxis was not approved by medical insurance in 9 %
of the infants born at\29 weeks of gestation, 12 % of the
infants 29–32 weeks of gestation, 42 % of the infants 32
1/7–35 weeks of gestation, 28 % of the infants with CHD,
and 10 % of the infants with CLD. Figure 2 shows medical
insurance coverage denials by risk group and medical
insurance. Infants with government medical insurance were
more likely to be denied prophylaxis (36 % denials vs.
24 % denials, p \ 0.01) and to receive fewer doses (two
doses vs. three doses, p \ 0.01).
Discussion
Palivizumab prophylaxis has been shown to reduce the
incidence of RSV hospitalization in at-risk infants [3, 5],
but effective prophylaxis requires full compliance with the
monthly dosing schedule [6]. Noncompliance is common
and may be the most controllable barrier to pharmacologic
prevention of RSV infection and its potentially severe
sequelae in high-risk infants [7]. Studies analyzing com-
pliance rates of palivizumab, defined in various ways
across the studies, have shown rates as low as 25 % to as
high as 100 % [8–10]. The compliance rates of patients in
clinical studies demonstrating reduced hospitalization rates
in high risk infants involved in palivizumab licensure were
92 and 93 % [3, 11]. Thus, compliance in routine practice
was more variable. In our study 74 % of the infants
received at least one dose of palivizumab, and \50 %
received the recommended maximum number of doses,
much less than in studies that demonstrated efficacy of
palivizumab.
Berger and colleagues assessed palivizumab use in
10,390 infants based on dispensing records for a pharmacy
benefits management company that provided follow-up
telephone contact to ensure the prescribed dose was
administered. A total of 9,675 (93 %) of 10,390 infants
were found to be compliant, defined as having no more
than 35 days between shipment of doses [12].
RSV hospitalization rates were 1.4 % in the compliant
group versus 3.1 % in the noncompliant group (OR 2.2,
95 % CI 1.4–3.5, p \ 0.001) [12]. Frogel and coworkers
also examined compliance and RSV hospitalization rates,
suggesting that improved compliance was associated with a
reduced risk of RSV hospitalization, consistent with the
clinical efficacy of palivizumab [13]. These studies show
that despite the progress that has been made in reducing
RSV hospitalization rates, infants whose parents are non-
compliant with palivizumab continue to have higher hos-
pitalization rates [12]. Our study shows high rates of
noncompliance. However, due to the nature of the study
design no clinical outcome data of the patients were
available and noncompliance cannot be correlated with
worse outcomes.
A systematic review of compliance with palivizumab
administration showed that the most common barriers that
influence or predict noncompliance with the recommended
regimen of RSV prophylaxis were parental smoking,
Medicaid enrollment, lower parental expectations for the
benefits of RSV prophylaxis, lack of transportation, and
language difficulties [14]. Our study showed similar results
with respect to medical insurance where infants with
government medical insurance were more likely to be
denied prophylaxis and to receive fewer doses. This finding
needs attention since palivizumab, when dosed consistent
with Food and Drug Administration (FDA) approved
labeling has been shown to be cost-effective among infants
enrolled in Medicaid [15].
The support services provided by specialty pharmacies
are now widely used to streamline the drug distribution,
delivery, and management process in ways that engage
patients in their care [16]. In a recently published article the
patients who were eligible to receive palivizumab pro-
phylaxis had a 18 % higher likelihood of receiving the
2009 AAP recommended doses when they were adminis-
tered through a specialty pharmacy rather than a traditional
pharmacy. The analysis found that 83 % of infants who
obtained their palivizumab from a specialty pharmacy
received the recommended doses, compared to 66 % who
received their medication from a non-specialty pharmacy,
thus emphasizing how specialty pharmacies can improve
patient compliance and treatment course completion [17].
In Puerto Rico, specialty pharmacies have distributed,
managed insurance approvals, and delivered palivizumab
since RSV prophylaxis started in 1999, but compliance
remains poor. The reasons for this are unclear and should
be investigated.
A procedure involving extensive counseling of parents,
reminder telephone calls on the day prior to the
Fig. 2 Palivizumab coverage denial by eligible risk group and
medical insurance
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appointment, calendars with reminder stickers, and track-
ing charts in the nursing medication rooms was used to
improve compliance in a hospital-based clinic. Results
showed that an increased percentage of infants (71 %)
received the appropriate number of injections after imple-
mentation of the new interventions compared with 25 %
before the new interventions [8]. Some authors have
reported that a home care strategy for administration of
palivizumab was associated with better compliance with
therapy by offering consistent delivery of medication and
ongoing parent/caregiver education. Based on these stud-
ies, a home-based program to administer RSV immuno-
prophylaxis was proposed as a key component in ensuring
compliance during the RSV season. Most barriers that
affect compliance could be overcome, providing greater
opportunity to educate parents or caregivers on the risks of
severe RSV disease and the benefits of prophylaxis. A
home-based delivery system might offer some additional
benefit of decreasing exposure of the infant to pathogens,
including RSV, in the clinic or office setting [14]. A
strategy like this one may help Puerto Rican infants
improve their compliance by eliminating the intermediary
between the specialty pharmacy and the patient. At present,
the specialty pharmacies deliver prophylaxis to the pedia-
tricians’ office and they administer it. With this approach
doses may be missed or administered at longer intervals as
they depend on the parents taking the child to the office for
administration. The development of a reminder system may
also help improve compliance.
It is critically important that parents of children at
high risk for severe RSV disease be empowered with
clear information about the seriousness of RSV disease
and the benefits of palivizumab prophylaxis to enable
them to make informed choices [6]. Physicians and other
health professionals are primary sources of information
for patients or their caregivers, and play a key role in
guiding families in their choices about RSV prophylaxis
and may play an important role in improving compliance
[6, 18].
Conclusions
Our study emphasizes the need to educate parents on the
serious consequences of RSV infection in high-risk patients
and the importance of administration of prophylaxis in the
recommended interval during the RSV season to prevent
RSV hospitalizations and their complications. Physicians
should be aware that many infants are not being dosed
appropriately and that strategies need to be established in
order to improve compliance. These strategies should
include working with payors to ensure that all infants who
qualify for prophylaxis are given approval for its use.
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